|
[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
黄健. 中国泌尿外科和男科疾病诊断治疗指南2019 版[M]. 北京: 科学出版社, 2020.
|
|
[3]
|
周利群, 李学松, 熊耕砚. 中国人群上尿路尿路上皮癌新进展[J]. 北京大学学报(医学版), 2014, 46(4): 504-506.
|
|
[4]
|
Martini, A., Daza, J., Poltiyelova, E., et al. (2019) Pathological Downstaging as a Novel Endpoint for the Development of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma. BJU International, 124, 665-671. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statis-tics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Pabla, N. and Dong, Z. (2008) Cisplatin Nephrotoxicity: Mechanismsand Renoprotective Strategies. Kidney International, 73, 994-1007. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Eastman, A. (1987) The Formation, Isolation and Characteri-zation of DNA Adducts Produced by Anticancer Platinum Complexes. Pharmacology & Therapeutics, 34, 155-166. [Google Scholar] [CrossRef]
|
|
[8]
|
Siddik, Z.H. (2003) Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance. Oncogene, 22, 7265-7279. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Cohen, S.M. and Lippard, S.J. (2001) Cisplatin: From DNA Damage to Cancer Chemotherapy. Progress in Nucleic Acid Research and Molecular Biology, 67, 93-130. [Google Scholar] [CrossRef]
|
|
[10]
|
Hastak, K., Alli, E. and Ford, J.M. (2010) Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly (ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin. Cancer Research, 70, 7970-7980. [Google Scholar] [CrossRef]
|
|
[11]
|
Hu, X.C., Zhang, J., Xu, B.H., Cai, L., Ragaz, J., Wang, Z.H., Wang, B.Y., Teng, Y.E., Tong, Z.S., Pan, Y.Y., Yin, Y.M., Wu, C.P., Jiang, Z.F., Wang, X.J., Lou, G.Y., Liu, D.G., Feng, J.F., Luo, J.F., Sun, K., Gu, Y.J., Wu, J. and Shao, Z.M. (2015) Cisplatin plus Gemcitabine versus Paclitax-elplus Gemcitabine as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (CBCSG006): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Oncology, 16, 436-446. [Google Scholar] [CrossRef]
|
|
[12]
|
Zhang, J., Lin, Y., Sun, X.J., Wang, B.Y., Wang, Z.H., Luo, J.F., Wang, L.P., Zhang, S., Cao, J., Tao, Z.H., Wu, J., Shao, Z.M., Yang, W.T. and Hu, X.C. (2018) Biomarker As-sessment of the CBCSG006 Trial: A Randomized Phase III Trial of Cisplatin plus Gemcitabine Compared with Paclitaxel plus Gemcitabine as First-Line Therapyfor Patients with Metastatic Triple-Negative Breast Cancer. Annals of Oncology, 29, 1741-1747. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Murphy, C.G. and Seidman, A.D. (2009) Evolving Approaches to Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes. Clinical Breast Cancer, 9, S58-S65. [Google Scholar] [CrossRef]
|
|
[14]
|
Kim, J.S., Park, I.H., Lee, K.S. and Ro, J. (2014) Out-comes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer Patients. Journal of Breast Cancer, 17, 339-343. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Erten, C., Demir, L., Somali, I., Alacacioglu, A., Kucukzeybek, Y., Akyol, M., Can, A., Dirican, A., Bayoglu, V. and Tarhan, M.O. (2013) Cisplatin plus Gemcitabine for Treatment of Breast Cancer Patients with Brain Metastases: A Preferential Option for Triple Negative Patients? Asian Pacific Journal of Cancer Prevention, 14, 3711-3717. [Google Scholar] [CrossRef]
|
|
[16]
|
Bodnar, L., Wcislo, G., Gasowska-Bodnar, A., Synowiec, A., Szarlej-Wcislo, K. and Szczylik, C. (2008) Renal Protection with Magnesium Subcarbonate and Magnesium Sulphate in Patients with Epithelial Ovarian Cancer after Cisplatin and Paclitaxel Chemotherapy: A Randomised Phase II Study. Eu-ropean Journal of Cancer, 44, 2608-2614. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Mehta, R.L., Awdishu, L., Davenport, A., Murray, P.T., Macedo, E., Cerda, J., Chakaravarthi, R., Holden, A.L. and Goldstein, S.L. (2015) Phenotype Standardization for Drug-Induced Kidney Disease. Kidney International, 88, 226-234. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Oh, G.S., Kim, H.J., Shen, A., Lee, S.B., Khadka, D., Pandit, A. and So, H.S. (2014) Cisplatin-Induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies. Electrolyte Blood Press, 12, 55-65. [Google Scholar] [CrossRef]
|
|
[19]
|
Daugaard, G., Abildgaard, U., Holstein-Rathlou, N.H., Bruunshuus, I., Bucher, D. and Leyssac, P.P. (1988) Renal Tubular Function in Patients Treated with High-Dose Cisplatin. Clinical Pharmacology & Therapeutics, 44, 164-172. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Oka, T., Kimura, T., Suzumura, T., Yoshimoto, N., Nakai, T., Yama-moto, N., Matsuura, K., Mitsuoka, S., Yoshimura, N., Kudoh, S. and Hirata, K. (2014) Magnesium Supplementation and High Volume Hydration Reduce the Renal Toxicity Caused by Cisplatin-Based Chemotherapy in Patients with Lung Cancer: A Toxicity Study. BMC Pharmacology and Toxicology, 15, Article No. 70. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Lajer, H. and Daugaard, G. (1999) Cisplatin and Hypomagnesemia. Cancer Treatment Reviews, 25, 47-58. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Hodgkinson, E., Neville-Webbe, H.L. and Coleman, R.E. (2006) Magnesium Depletion in Patients Receiving Cisplatin-Based Chemotherapy. Clinical Oncology, 18, 710-718. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Miller, R.P., Tadagavadi, R.K., Ramesh, G. and Reeves, W.B. (2010) Mechanisms of Cisplatin Nephrotoxicity. Toxins, 2, 2490-2518. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Crona, D.J., Faso, A., Nishijima, T.F., McGraw, K.A., Galsky, M.D. and Milowsky, M.I. (2017) A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist, 22, 609-619. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Aalbersberg, E.A., Rossi, M.M., de Wit-van der Veen, L.J., Walraven, I., van den Heuvel, M.M., Sonke, J.J., Belderbos, J.S. and Vogel, W.V. (2019) Prehydration in Cispla-tin-Based CCRT: Effects on Tumour Concentrations and Treatment Outcome. Radiotherapy & Oncology, 134, 30-36. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Biedermann, B., Landmann, C., Kann, R., Passweg, J., Soler, M., Lohri, A., Rochlitz, C., Herrmann, R. and Pless, M. (2000) Combined Chemoradiotherapy with Daily Low-Dose Cisplatin in Locally Advanced Inoperable Non-Small Cell Lung Cancer. Radiotherapy & amp; Oncology, 56, 169-173. [Google Scholar] [CrossRef]
|
|
[27]
|
Hazuka, M.B., Crowley, J.J., Bunn Jr., P.A., O’Rourke, M., Braun, T.J. and Livingston, R.B. (1994) Daily Low-Dose Cisplatin plus Concurrent Highdose Thoracic Irradiation in Locally Advanced Unresectable Non-Small-Cell Lung Cancer: Results of a Phase II Southwest Oncology Group Study. Journal of Clinical Oncology, 12, 1814-1820. [Google Scholar] [CrossRef]
|
|
[28]
|
白春梅, 徐光勋, 赵永强, 等. 重组人血小板生成素治疗实体肿瘤患者化疗后血小板减少的多中心临床试验[J]. 中国医学科学院学报, 2004, 26(4): 437-441.
|
|
[29]
|
Vadhan-Raj, S., Murray, L.J., Bueso-Ramos, C., et al. (1997) Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer. Annals of Internal Medi-cine, 126, 673-681. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Semb, S., Helgstrand, F., Hjorne, F. and Bytzer, P. (2017) Persistent Severe Hypomagnesemia Caused by Proton Pump Inhibitor Resolved after Laparoscopic Fundopli-cation. World Journal of Gastroenterology, 23, 6907-6910. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Besic, N., Zagar, S., Pilko, G., Peric, B. and Hocevar, M.J.R. (2008) Influence of Magnesium Sulphate Infusion before Total Thyroidectomyon Transient Hypocalcemia—A Randomised Study. Radiology and Oncology, 42, 143-150 [Google Scholar] [CrossRef]
|
|
[32]
|
Jiang, D.M., Dennis, K., Steinmetz, A., Clemons, M., Asmis, T.R., Goodwin, R.A. and Vickers, M.M. (2016) Management of Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesemia: A Systematic Review. Clinical Colorectal Cancer, 15, e117-e123. [Google Scholar] [CrossRef] [PubMed]
|